XTL Biopharmaceuticals (XTLB) Stock: Buy, Sell, or Hold?
XTLB - XTL Biopharmaceuticals Ltd. American Depositary Shares
$2.02
0.05 (2.54%)
▲
5d:
+3.06%
30d:
-16.19%
90d:
-30.82%
BUY
HIGH Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Apr 29, 2026
0d
Get Alerted When XTLB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: XTLB shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
✅ BUY SIGNAL: XTLB shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
In-depth Analysis How we analyze
Valuation Analysis: XTLB is currently trading at $2.02, which is considered slightly low relative to its 30-day fair value range of $1.93 to $2.30.
Technical Outlook: Technically, XTLB is in a downtrend. The price is approaching resistance at $2.02. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: XTLB scores 83/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $30.00 (+1385.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, XTLB is in a downtrend. The price is approaching resistance at $2.02. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: XTLB scores 83/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $30.00 (+1385.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$1.93 -
$2.30
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
94.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (83/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 1385.1% below Wall St target ($30.00)
- BULLISH: Bottoming setup score 83/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$1.93 -
$2.30
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$1.78
Resistance Level
$2.02
Current Trend
Downtrend
Technical data as of
Oct 23, 2026
Fundamental Context
Wall Street Target
$30.00
(+1385.1%)
Earnings Growth (YoY)
-76.0%
Share & Embed Analysis
Last updated: October 24, 2026 7:20 AM ET
Data refreshes hourly during market hours. Next update: 8:20 AM
Data refreshes hourly during market hours. Next update: 8:20 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is XTLB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$369 | 52 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
27 analysts |
$436 | 38 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
21 analysts |
$307 | 51 HOLD |
|
RYTM
Rhythm Pharmaceuticals I… |
STRONG BUY
18 analysts |
$144 | 75 BUY |
|
PVLA
Palvella Therapeutics, I… |
STRONG BUY
15 analysts |
$231 | 60 HOLD |